Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors

Third Cell Therapy For Lymphoma Approved In The US

 
• By Mary Jo Laffler and Mandy Jackson

Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah. 

FDA - Food and Drug Administration approved text on document above stethoscope
Breyanzi was approved after an FDA delay related to manufacturing inspections • Source: Shutterstock

The US Food and Drug Administration approval of Bristol Myers Squibb Company’s chimeric antigen receptor T-cell (CAR-T) therapy Breyanzi (lisocabtagene maraleucel; liso-cel) has been a long time coming, but that has given the company time to prepare for launch against two established competitors.

The FDA cleared Breyanzi on 5 February to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment; labeling notes that it is not intended to treat primary central nervous system lymphoma

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip